WO1999061049A3 - Model for infection by a pathogen using administration of nucleic acids - Google Patents

Model for infection by a pathogen using administration of nucleic acids Download PDF

Info

Publication number
WO1999061049A3
WO1999061049A3 PCT/US1999/011251 US9911251W WO9961049A3 WO 1999061049 A3 WO1999061049 A3 WO 1999061049A3 US 9911251 W US9911251 W US 9911251W WO 9961049 A3 WO9961049 A3 WO 9961049A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathogen
infection
model
nucleic acids
administration
Prior art date
Application number
PCT/US1999/011251
Other languages
French (fr)
Other versions
WO1999061049A2 (en
Inventor
Shan Lu
John E Herrmann
Original Assignee
Univ Massachusetts Medical
Shan Lu
John E Herrmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts Medical, Shan Lu, John E Herrmann filed Critical Univ Massachusetts Medical
Publication of WO1999061049A2 publication Critical patent/WO1999061049A2/en
Publication of WO1999061049A3 publication Critical patent/WO1999061049A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods are described for generating a model for infection of a host by a pathogen of interest, such as an immunodeficiency virus, and for generating organisms for use in a live, attenuated vaccine against a pathogen, by administering nucleic acids from the pathogen to the host.
PCT/US1999/011251 1998-05-22 1999-05-20 Model for infection by a pathogen using administration of nucleic acids WO1999061049A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8355798A 1998-05-22 1998-05-22
US09/083,557 1998-05-22

Publications (2)

Publication Number Publication Date
WO1999061049A2 WO1999061049A2 (en) 1999-12-02
WO1999061049A3 true WO1999061049A3 (en) 2000-02-03

Family

ID=22179108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011251 WO1999061049A2 (en) 1998-05-22 1999-05-20 Model for infection by a pathogen using administration of nucleic acids

Country Status (1)

Country Link
WO (1) WO1999061049A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000987A1 (en) * 1990-07-12 1992-01-23 President And Fellows Of Harvard College Primate lentivirus vaccines
US5654195A (en) * 1992-05-22 1997-08-05 Dana-Farber Cancer Institute Vectors expressing hybrid viruses, methods of use and novel assays
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000987A1 (en) * 1990-07-12 1992-01-23 President And Fellows Of Harvard College Primate lentivirus vaccines
US5654195A (en) * 1992-05-22 1997-08-05 Dana-Farber Cancer Institute Vectors expressing hybrid viruses, methods of use and novel assays
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
FULLER D H ET AL: "INDUCTION OF IMMUNODEFICIENCY VIRUS-SPECIFIC IMMUNE RESPONSES IN RHESUS MONKEYS FOLLOWING GENE GUN-MEDIATED DNA VACCINATION", JOURNAL OF MEDICAL PRIMATOLOGY,DK,MUNKSGAARD, COPENHAGEN, vol. 25, no. 3, 1996, pages 236-241, XP002034929, ISSN: 0047-2565 *
HULSKOTTE ET AL.: "TOWARDS AN HIV-1 VACCINE: LESSONS FROM STUDIES IN MACAQUE MODELS", VACCINE, vol. 16, May 1998 (1998-05-01), pages 904 - 915, XP002123025 *
JOAG ET AL.: "ANIMAL MODEL OF MUCOSALLY TRANSMITTED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 DISEASE: INTRAVAGINAL AND ORAL DEPOSITION OF SIMIAN/HUMAN IMMUNODEFICIENCY VIRUS IN MACAQUES RESULTS IN SYSTEMIC INFECTION, ELIMINATION OF CD4+ T CELLS, AND AIDS", J.VIROL., vol. 71, no. 5, May 1997 (1997-05-01), pages 4016 - 4023, XP002077809 *
LETVIN ET AL.: "RISKS OF HANDLING HIV", NATURE, vol. 349, 1991, pages 573, XP002123018 *
LU ET AL.: "SIMIAN IMMUNODEFICIENCY VIRUS DNA VACCINE TRIAL IN MACAQUES", J.VIROL., vol. 70, no. 6, 1996, pages 3978 - 3991, XP002123021 *
LU S.: "DEVELOPING DNA VACCINES AGAINST IMMUNODEFICIENCY VIRUSES", CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 226, 1998, pages 161 - 173, XP002123022 *
R DESROSIERS: "HIV with multiple gene deletion as a live attenuated vaccine for AIDS", AIDS RESEARCH AND HUMAN RETROVIRUSES,US,NEW YORK, NY, vol. 8, no. 8, 1992, pages 1457, XP002077807, ISSN: 0889-2229 *
RUPRECHT ET AL.: "ORAL SIV, SHIV, AND HIV TYPE 1 INFECTION", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 14 Suppl. 1, April 1998 (1998-04-01), pages S-97 - S-103, XP002123024 *
SHING C C ET AL: "Protective immunity induced by rotavirus DNA vaccines", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 15, no. 8, 1997, pages 899-902, XP004075680, ISSN: 0264-410X *
SIMPSON ET AL.: "SOURCE AND ROUTE OF EXPOSURE INFLUENCE INFECTIVITY OF A MOLECULAR CLONE OF HUMAN T CELL LEUKEMIA VIRUS TYPE I", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 14, no. 8, May 1998 (1998-05-01), XP002123020 *
SODORQA ET AL.: "VAGINAL TRANSMISSION OF SIV: ASSESSING INFECTIVITY AND HORMONAL INFLUENCES IN MACAQUES INOCULATED WITH CELL-FREE AND CELL-ASSOCIATED VIRAL STOCKS", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 14 Suppl. 1, April 1998 (1998-04-01), pages S-119 - S-123, XP002123023 *
ZHAO ET AL.: "INFECTIVITY OF CHIMERIC HUMAN T-CELL LEUKEMIA VIRUS TYPE I MOLECULAR CLONES ASSESSED BY NAKED DNA INOCULATION", PNAS, vol. 93, 1996, pages 6653 - 6658, XP002123019 *

Also Published As

Publication number Publication date
WO1999061049A2 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
EE9900343A (en) Synthetic Polynucleotide, Immune Response Method, Immunogenic Composition, Anti-HIV Immune Response Induction Method, Antigen-Inducing Cell Indication, and Pharmaceutical Composition
EP1200109A4 (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
DE60130569D1 (en) PACKAGING REPLICON PARTICLES OF POSITIVE-STRAND RNA RNA
EP1847549A3 (en) Papillomavirus polyprotein constructs
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
EP1687329B8 (en) Optimized expression of hpv 58 l1 in yeast
PT1212358E (en) SYNTHETIC GENES OF HUMAN PAPILOMAVIRUS
AU4622693A (en) Potentiation of immunogenic response
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
CY1107950T1 (en) NAVIGATION VACCINE COMPOSITIONS AND METHODS
DK1024824T3 (en) Solid form dispersing vaccine composition for oral administration
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
WO2004032860A3 (en) Hiv vaccine formulations
MX2007013472A (en) Vaccine.
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
AUPQ797700A0 (en) Vaccine
MXPA03009763A (en) Foot and mouth disease virus vaccine.
WO1999061049A3 (en) Model for infection by a pathogen using administration of nucleic acids
WO2002009749A3 (en) Respiratory syncytial virus vaccine
WO2002044384A3 (en) T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy
WO2005027844A3 (en) Dna vaccine compositions and methods of use
WO2001034185A3 (en) Induction of mucosal immunity by vaccination via the skin route
CA2363493A1 (en) Attenuated forms of bovine viral diarrhea virus
WO1999056772A3 (en) Hepatitis vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase